Feasibility study of stereotactic body radiotherapy for prostate cancer

Feasibility study of stereotactic body radiotherapy for prostate cancer - Feasibility study of CyberKnife for prostate cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009615

Enrollment

Registered

2012-12-24

Start date

2012-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early stage prostate cancer (T1-T2c and iPSA 10-20 ng/mL and GS=&lt

Interventions

Radiotherapy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Adenocarcinoma 2) Low risk (T1-T2a and iPSA <10 ng/mL and GS=<6), or a partof Intermediate risk (T1-T2a and iPSA 10-20 ng/mL and GS=<6, or T1-T2a and iPSA <10 ng/mL and GS=7) 3) 50-84 years 4) No hormonral therapy or less than 8 months 5) PS 0-1 6) No privious radiotherapy histoly 7) Written informed consent

Exclusion criteria

Exclusion criteria: 1) active double cancer(s) 2) Uncontrol DM 3) collagen disease, heart failure, sever respiratoy disease 4) Mental disease 5) Major operation of pelvic site 6) Surgery for prostate cancer 7) Chemotherapy for prostate cancer 8) Crohn's disease, Uncerlative colitis 9) Anti-coagulation agent 10) IPSS =<20 11) Artificial head

Design outcomes

Primary

Measure	Time frame
Rate of acute adverse events	—

Secondary

Measure	Time frame
2-year PSA failure rate, 2-year clinical failure rate, recurrence pattern, late adverse events, rate of perprotocol, evaluation of dose distribution	—

Countries

Japan

Contacts

Public ContactNaoto Shikama

Saitama Medical University, International Medical Center Radiation Oncology

nshikama0525@gmail.com042-984-4136

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026